# Pemazyre (pemigatinib) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/pemigatinib

> The FDA approved Pemazyre (pemigatinib), sponsored by INCYTE CORP (INCY), on April 17, 2020.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Pemazyre (pemigatinib) |
| Codes | INCB054828 |
| Sponsor | INCYTE CORP (INCY) https://sec-api.dev/companies/incy/catalysts |
| Indications | [Endometrial Cancer](https://sec-api.dev/indications/endometrial-cancer), Unresectable Cholangiocarcinoma |
| Modality |  |
| FDA designations | priority review |

## Timeline

### April 17, 2020: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA213736 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20200417, review_priority PRIORITY; sponsor_name INCYTE CORP; product PEMAZYRE (PEMIGATINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213736%22

### August 26, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA213736 SUPPL-2 (Efficacy): submission_status AP, submission_status_date 20220826, review_priority PRIORITY; sponsor_name INCYTE CORP; product PEMAZYRE (PEMIGATINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213736%22

### July 7, 2025: primary completion

- Status: withdrawn. Date confidence: exact. Stage: 3. Indication: Unresectable Cholangiocarcinoma; Metastatic Cholangiocarcinoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03656536 (A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-07-07 (ACTUAL); Lead Sponsor Incyte Corporation; Results First Posted 2026-08-11." https://clinicaltrials.gov/study/NCT03656536

### May 29, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Endometrial Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04463771 (Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-05-29 (ACTUAL); Lead Sponsor Incyte Corporation." https://clinicaltrials.gov/study/NCT04463771

## Same indication

- [Bnt323/db-1303](https://sec-api.dev/pdufa/bnt323-db-1303) (BNTX)
- [Datopotamab deruxtecan (dato-dxd)](https://sec-api.dev/pdufa/datopotamab-deruxtecan-dato-dxd) (AZN)
- [Amtagvi® (lifileucel)](https://sec-api.dev/pdufa/lifileucel) (IOVA)
- [Puxitatug samrotecan](https://sec-api.dev/pdufa/puxitatug-samrotecan) (AZN)
- [Rina-s](https://sec-api.dev/pdufa/rina-s) (GMAB)
- [Sacituzumab govitecan-hziy](https://sec-api.dev/pdufa/sacituzumab-govitecan-hziy) (GILD)
- [Sacituzumab tirumotecan](https://sec-api.dev/pdufa/sacituzumab-tirumotecan) (MRK)
- [Sapanisertib](https://sec-api.dev/pdufa/sapanisertib) (FTH)
- [ENHERTU (trastuzumab deruxtecan)](https://sec-api.dev/pdufa/trastuzumab-deruxtecan) (AZN)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/pemigatinib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Pemazyre (pemigatinib) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/pemigatinib

```bibtex
@misc{secapidev_pdufa_pemigatinib_20261116,
  title        = {Pemazyre (pemigatinib) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/pemigatinib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_pemigatinib_20261116","title":"Pemazyre (pemigatinib) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/pemigatinib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
